Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study

被引:0
作者
Sarah J. Hallberg
Amy L. McKenzie
Paul T. Williams
Nasir H. Bhanpuri
Anne L. Peters
Wayne W. Campbell
Tamara L. Hazbun
Brittanie M. Volk
James P. McCarter
Stephen D. Phinney
Jeff S. Volek
机构
[1] Indiana University Health Arnett,Medically Supervised Weight Loss
[2] Virta Health,Keck School of Medicine
[3] Independent Consultant,Department of Nutrition Science
[4] University of Southern California,Department of Genetics
[5] Purdue University,Department of Human Sciences
[6] Washington University School of Medicine,undefined
[7] The Ohio State University,undefined
来源
Diabetes Therapy | 2018年 / 9卷
关键词
Beta-hydroxybutyrate; Carbohydrate restriction; HbA1c; Ketosis; Type 2 diabetes; Weight loss;
D O I
暂无
中图分类号
学科分类号
摘要
Treatments for type 2 diabetes (T2D) have improved, yet T2D and being overweight are still significant public health concerns. Blood sugar in patients with T2D can improve quickly when patients eat significantly fewer dietary carbohydrates. However, this demands careful medicine management by doctors, and patients need support and frequent contact with health providers to sustain this way of living. The purpose of this study was to evaluate if a new care model with very low dietary carbohydrate intake and continuous supervision by a health coach and doctor could safely lower HbA1c, weight and need for medicines after 1 year in adults with T2D. 262 adults with T2D volunteered to participate in this continuous care intervention (CCI) along with 87 adults with T2D receiving usual care (UC) from their doctors and diabetes education program. After 1 year, patients in the CCI, on average, lowered HbA1c from 7.6 to 6.3%, lost 12% of their body weight, and reduced diabetes medicine use. 94% of patients who were prescribed insulin reduced or stopped their insulin use, and sulfonylureas were eliminated in all patients. Participants in the UC group had no changes to HbA1c, weight or diabetes medicine use over the year. These changes in CCI participants happened safely while dyslipidemia and markers of inflammation and liver function improved. This suggests the novel care model studied here using dietary carbohydrate restriction and continuous remote care can safely support adults with T2D to lower HbA1c, weight, and medicine use.
引用
收藏
页码:583 / 612
页数:29
相关论文
共 155 条
  • [41] Stein TP(2014)Incidence of remission in adults with type 2 diabetes: the diabetes & aging study Diabetes Care 37 3188-2762
  • [42] Shimazu T(2017)Evidence that supports the prescription of low-carbohydrate high-fat diets: a narrative review Br J Sports Med 51 133-256
  • [43] Hirschey MD(2017)An online intervention comparing a very low-carbohydrate ketogenic diet and lifestyle recommendations versus a plate method diet in overweight individuals with type 2 diabetes: a randomized controlled trial J Med Internet Res 19 e36-undefined
  • [44] Newman J(2016)Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes Obesity 24 2269-undefined
  • [45] Youm Y-H(1972)Resistance to symptomatic insulin reactions after fasting J Clin Invest 51 2757-undefined
  • [46] Nguyen KY(2007)Beneficial effects of ketogenic diet in obese diabetic subjects Mol Cell Biochem 302 249-undefined
  • [47] Grant RW(undefined)undefined undefined undefined undefined-undefined
  • [48] Yancy WS(undefined)undefined undefined undefined undefined-undefined
  • [49] Olsen MK(undefined)undefined undefined undefined undefined-undefined
  • [50] Guyton JR(undefined)undefined undefined undefined undefined-undefined